Streetbeat News

Stock Prices

MEDP

Medpace Holdings (NYSE:MEDP) has seen a decrease in short interest, now at 5.04% of its float, down 3.08% from the last report. With 1.02 million shares sold short, it would take about 5.73 days to cover all short positions. This decline in short interest could indicate a more bullish sentiment towards MEDP among investors. Compared to its peers, MEDP has a lower short interest percentage, with the average for its peer group at 5.57%.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:00 pm

FRGT

Trading of Freight Technologies shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:00 pm

WRAP

Trading for WRAP Technologies was halted at 9:00:00 a.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:00 pm

AAPL

NVDA

Huawei Technologies Co has shifted its focus towards AI, impacting its Mate 60 smartphone production, to compete with Nvidia Corp's AI chips, particularly in the Chinese market. Nvidia has launched the H20 AI chip, priced between $12,000 and $15,000, to compete with Huawei's 910B chip. The U.S. has tightened AI chip sales to China, prompting a shift towards domestic options like Huawei's Ascend series. Despite challenges, Huawei leads Chinese smartphone sales, and Nvidia's shares rose by 3.07% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

February 05, 2024 | 1:58 pm

CHTR

Charter Communications, Inc (NASDAQ:CHTR) reported weaker-than-expected Q4 earnings, with revenue slightly above consensus but EPS below expectations. The company saw growth in Internet, Mobile service, and Commercial sectors, and expects higher Capex for 2024. Shares fell 16.5% after the announcement. Analysts from JP Morgan and Barclays adjusted their price targets and ratings for CHTR following the earnings report.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:58 pm

EL

Estee Lauder (NYSE:EL) shares surged premarket after reporting Q2 FY24 results that exceeded expectations, with a sales decline of 7% Y/Y to $4.279 billion, surpassing analyst estimates. The company also announced a quarterly dividend of $0.66 per share and revised its FY24 outlook. Additionally, Estee Lauder is expanding its Profit Recovery Plan, aiming for significant operating profit increases by FY26.

Portfolio Pulse from Lekha Gupta

February 05, 2024 | 1:56 pm

VALN

Valneva SE (NASDAQ:VALN) sold an FDA Priority Review Voucher for $103 million, awarded for the approval of Ixchiq, the first licensed chikungunya vaccine. The proceeds will fund R&D, including Phase 3 Lyme disease vaccine trials and further chikungunya vaccine trials. Valneva reported positive 24-month antibody persistence data for Ixchiq. The global market for chikungunya vaccines is expected to exceed $500 million annually by 2032. VALN shares are down 1.11% in premarket trading.

Portfolio Pulse from Vandana Singh

February 05, 2024 | 1:55 pm

VLCN

Trading for VLCN was halted and then resumed at 8:55:00 AM ET, following an update on its status.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:55 pm

GTBP

Trading for GTBP was halted and then resumed at 8:55:00 AM ET, following an update on its status.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:55 pm

FRGT

Trading for FRGT was halted and then resumed at 8:55:00 AM ET, with updates on quotation resumption, news, and resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:55 pm